The application of IL-6 blockers as anticancer agents has been investigated in many cancer types, including lung cancer, multiple myeloma, B-cell non-Hodgkin's lymphoma, prostate cancer, renal cell carcinoma, ovarian cancer, and also in oral mucositis in head and neck cancer, and cachexia related to lung cancer [13]. This evidence concerns the gene IL6 and lung carcinoma.